Lipocine Initiates New ATM Offering, Ends Previous Agreement
Company Announcements

Lipocine Initiates New ATM Offering, Ends Previous Agreement

Lipocine (LPCN) has shared an update.

Lipocine Inc. has entered into a new at-the-market (ATM) agreement with A.G.P./Alliance Global Partners to offer and sell up to $10.6 million in shares. This move comes as the company terminated its previous sales agreement with Cantor Fitzgerald & Co. to facilitate this new arrangement. The shares will be sold through A.G.P. using methods allowed by law, including sales on the Nasdaq Capital Market, and A.G.P. will receive a commission of 3% on gross proceeds. Both parties retain the right to terminate the agreement with ten days’ notice, and the offering will continue only until the agreement expires or is terminated.

Learn more about LPCN stock on TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistLPCN Earnings this Week: How Will it Perform?
TheFlyLipocine inks distribution, license agreement with SPC Korea for Tlando
TheFlyLipocine’s brexanolone shows positive quantitative EEG results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App